FDA-cleared profile

CINA-iPE

Avicenna.AI · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Worklist triage and notification for suspected incidental pulmonary embolism on contrast-enhanced CT acquired for another indication; not a diagnostic device

Clinical role
Standalone triage application operating in parallel with standard of care; all studies appear in the worklist, flagged series receive notification and passive marking, and the original images remain the basis for review
Images and patients
CT/CTA · Lung and pulmonary arterial segments containing incidental pulmonary embolism; subsegmental arteries are out of scope
Key limitation
Keep in mind: Not designed to detect PE in subsegmental arteries; preview images are informational and not diagnostic; results are not for standalone diagnosis and notified clinicians must review the full study using standard of care; the input is CT for another indication rather than a dedicated CTPA protocol

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Worklist triage and notification for suspected incidental pulmonary embolism on contrast-enhanced CT acquired for another indication; not a diagnostic device
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Lung and pulmonary arterial segments containing incidental pulmonary embolism; subsegmental arteries are out of scope Input: DICOM contrast-enhanced CT scans, not dedicated CTPA, including at least part of the lung; intended for adults and transitional adolescents aged 18-21 treated as adults
  • Who uses it?Intended users: Hospital networks and trained radiologists
  • What does the software produce?Output: Passive worklist icon and active notification for suspected incidental PE, with a compressed grayscale unannotated preview marked not for diagnostic use; results files are transferred for PACS/workstation prioritization and the original image is not altered
  • What is its most important limitation?Key limitation: Not designed to detect PE in subsegmental arteries; preview images are informational and not diagnostic; results are not for standalone diagnosis and notified clinicians must review the full study using standard of care; the input is CT for another indication rather than a dedicated CTPA protocol

Clinical takeaway. Clinical role: Worklist triage and notification for suspected incidental pulmonary embolism on contrast-enhanced CT acquired for another indication; not a diagnostic device

Evidence takeaway. Evidence from the reviewed source record: Retrospective multicenter, multinational, blinded standalone study of 381 cases: 181 positive and 200 negative, with ground truth by consensus of three US-board-certified expert radiologists. Global sensitivity was 87.8% (95% CI 82.2%-92.2%) and specificity 92.0% (87.3%-95.4%) against an 80% performance goal. Sensitivity by overlapping lesion-location groups was main 96.3%, interlobar 94.5%, lobar 92.9%, and segmental 88.3%. Mean time-to-notification was 1.5 minutes for all cases and 1.5 minutes for 159 true-positive cases

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Worklist triage and notification for suspected incidental pulmonary embolism on contrast-enhanced CT acquired for another indication; not a diagnostic device
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Standalone triage application operating in parallel with standard of care; all studies appear in the worklist, flagged series receive notification and passive marking, and the original images remain the basis for review
  • Exact FDA submission
  • Checked 2026-09-08
Required input
DICOM contrast-enhanced CT scans, not dedicated CTPA, including at least part of the lung; intended for adults and transitional adolescents aged 18-21 treated as adults
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Passive worklist icon and active notification for suspected incidental PE, with a compressed grayscale unannotated preview marked not for diagnostic use; results files are transferred for PACS/workstation prioritization and the original image is not altered
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Hospital radiology worklist workflow for adults and transitional adolescents aged 18-21 treated as adults
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Hospital networks and trained radiologists
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Not designed to detect PE in subsegmental arteries; preview images are informational and not diagnostic; results are not for standalone diagnosis and notified clinicians must review the full study using standard of care; the input is CT for another indication rather than a dedicated CTPA protocol
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
Retrospective multicenter, multinational, blinded standalone study of 381 cases: 181 positive and 200 negative, with ground truth by consensus of three US-board-certified expert radiologists. Global sensitivity was 87.8% (95% CI 82.2%-92.2%) and specificity 92.0% (87.3%-95.4%) against an 80% performance goal. Sensitivity by overlapping lesion-location groups was main 96.3%, interlobar 94.5%, lobar 92.9%, and segmental 88.3%. Mean time-to-notification was 1.5 minutes for all cases and 1.5 minutes for 159 true-positive cases
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Retrospective multicenter, multinational, blinded standalone study of 381 cases: 181 positive and 200 negative, with ground truth by consensus of three US-board-certified expert radiologists. Global sensitivity was 87.8% (95% CI 82.2%-92.2%) and specificity 92.0% (87.3%-95.4%) against an 80% performance goal. Sensitivity by overlapping lesion-location groups was main 96.3%, interlobar 94.5%, lobar 92.9%, and segmental 88.3%. Mean time-to-notification was 1.5 minutes for all cases and 1.5 minutes for 159 true-positive cases
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
87.8% (95% CI: 82.2%, 92.2%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
92.0% (95% CI: 87.3%, 95.4%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

CINA-iPE regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K233968
  • Samplen=381
  • IndependenceIndependence not established

K233968

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K233968. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM contrast-enhanced CT scans, not dedicated CTPA, including at least part of the lung; intended for adults and transitional adolescents aged 18-21 treated as adults

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K233968: CINA-iPE

  2. Routing

    Source context, not route validation: CINA-iPE can run with the CINA Platform cleared under K200855 or another medical image communications device. DICOM services communicate with CT modalities, routers, PACS, and the Worklist Application; exact local interface versions are not established

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K233968: CINA-iPE

  3. AI processing

    Source context, not route validation: The exact FDA package describes CINA-iPE running on a standard off-the-shelf server/workstation, with an Image Processing Application that can be integrated, deployed, and used with the CINA Platform (K200855) or other medical image communications devices. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "CINA-iPE runs on a standard “off the shelf” server/workstation and consists of an Image Processing Application, which can be integrated, deployed, and used with the CINA Platform (cleared under K200855) or other medical image communications devices." … "The CINA platform is an example of medical image communications platform for integrating and deploying the CINA-iPE image processing application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K233968: CINA-iPE

  4. Returned objects

    Source context, not route validation: Passive worklist icon and active notification for suspected incidental PE, with a compressed grayscale unannotated preview marked not for diagnostic use; results files are transferred for PACS/workstation prioritization and the original image is not altered

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K233968: CINA-iPE

  5. Viewer/worklist/report

    Unresolved route: Passive worklist icon and active notification for suspected incidental PE, with a compressed grayscale unannotated preview marked not for diagnostic use; results files are transferred for PACS/workstation prioritization and the original image is not altered

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K233968: CINA-iPE

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes CINA-iPE running on a standard off-the-shelf server/workstation, with an Image Processing Application that can be integrated, deployed, and used with the CINA Platform (K200855) or other medical image communications devices. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "CINA-iPE runs on a standard “off the shelf” server/workstation and consists of an Image Processing Application, which can be integrated, deployed, and used with the CINA Platform (cleared under K200855) or other medical image communications devices." … "The CINA platform is an example of medical image communications platform for integrating and deploying the CINA-iPE image processing application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
CINA-iPE can run with the CINA Platform cleared under K200855 or another medical image communications device. DICOM services communicate with CT modalities, routers, PACS, and the Worklist Application; exact local interface versions are not established
  • Exact FDA submission
  • Checked 2026-09-08
Security
Avicenna.AI's cybersecurity page states ISO/IEC 27001 certification by SGS, IEC 81001-5-1, TLS 1.2+ in transit, encryption at rest, role-based access with least privilege, and a HIPAA business associate agreement for US customers. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for CINA-iPE; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K233968
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Lung and pulmonary arterial segments containing incidental pulmonary embolism; subsegmental arteries are out of scope
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-03-13
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
10Source classes checked
2Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K233968 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K233968: CINA-iPE

    U.S. Food and Drug Administration - Published 2024-03-13 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. CINA-iPE model card (K233968)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K233968

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. Avicenna.AI Cybersecurity and Data Protection

    Avicenna.AI - Accessed 2026-10-25

    Scope: security

Research history

  1. K233968 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251610

qER-CTA (v1.0)

Qure.ai Technologies

Authorized purpose: Parallel notification of suspected anterior-circulation large vessel occlusion on acute head CTA for specialist review; notification only, not diagnosis.

Modality
CT/CTA
Anatomy
Brain anterior circulation: internal carotid artery and M1 segment of the middle cerebral artery
Decision
2025-09-08
FDA-cleared K251151

Rapid CTA 360

iSchemaView

Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-07-16
FDA-cleared K243145

syngo.CT LVO Detection

Siemens Medical Solutions USA, Inc.

Authorized purpose: AI-assisted acute-care triage and notification of suspected large-vessel occlusion on contrast-enhanced head CTA to prioritize review; not diagnosis.

Modality
CT/CTA
Anatomy
Brain/head vasculature, specifically the ICA, M1, and M2 segments
Decision
2025-04-10
FDA-cleared K250248

BriefCase-Triage

Aidoc Medical, Ltd.

Authorized purpose: Parallel-workflow triage and notification of suspected incidental pulmonary embolism on contrast-enhanced images that include the lungs.

Modality
CT/CTA
Anatomy
Chest and lungs
Decision
2025-02-14

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history